 Johnson Johnson NYSE:JNJs wholly-owned pharmaceutical company Janssen Pharmaceuticals and its global research partners have discontinued their Phase 3 Mosaico study of Janssens investigational human immunodeficiency virus HIV vaccine after it was found not effective in preventing infections. The company said in a statement that no safety issues with the vaccine regimen were identified. 